Search

Breast cancer ranks as the most common female malignancy worldwide. Data from GLOBOCAN 2020 showed that breast cancer surpassed lung cancer and become the leading malignancy globally which was a serious threat to women's health. Different from Caucasian, there i a lower prevalence of breast cancer in Chinese women. However, the age-standardized incidence rate of breast cancer in China has reached to 39.1 per 100,000 in 2020, with 416,000 new cases, accounting for 18.4% of global breast cancer burden, due to multiple factors such as lifestyle and dietary habits changes in recent years. The treatment and prevention of breast cancer are becoming increasingly a tuff task. In addition, triple-negative breast cancer (TNBC) is a subtype with higher malignancy and worse prognosis. Due to lack of specific therapeutic targets, less treatment progress has been made in recent years. There is even less progress in the therapy of advanced TNBC, but huge unmet needs exist for further therapeutic optimization. Echoing advocacy from The Society of Breast Cancer China Anti-Cancer Association; International Medical Exchange Society, China Anti-Cancer Association; Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, top experts from multidisciplinary departments of breast cancer in China have consensus on this "Guidelines for clinical diagnosis and treatment of advanced triple-negative breast cancer in China (2024 edition)" according to the latest evidence based updates. We hope this pater can guide or optimize the precise therapeutic decision-making for advanced triple-negative breast cancer in China. [ABSTRACT FROM AUTHOR]

Copyright of China Oncology is the property of Editorial Board of China Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor among women in China. In 2016, there were about 306 000 new cases of breast cancer in Chinese females. Of these, about 33% (100 400) occurred in rural areas. County-level (counties or county-level cities) hospitals are the first diagnosis units for most rural breast cancer patients and play an important role in cancer prevention, screening, maintenance treatment, rehabilitation, follow-up, and referral. Due to economic and geographical constraints, county-level hospitals are relatively deficient in medical equipment, health human resources, and drug accessibility. There is an imperative need for breast cancer prevention and management guidelines that are suitable for the actual situation in China's counties. Therefore, under the policy background of hierarchical diagnosis and treatment, the Chinese expert group formulated the“Guideline for the management path and quality control of breast cancer prevention and treatment in China's counties (2023 edition)”, aiming to expand the availability of quality medical resources and ensure they are better distributed among regions, enhance the capacity for breast cancer prevention and treatment, so as to improve the prognosis and quality of life of patients in China's counties. This guideline provides path diagrams which are concise, unambiguous and easy to translate into clinical practice, as reference for clinicians in county-level hospitals [ABSTRACT FROM AUTHOR]

Breast cancer is the most common malignant tumor in women around the world, and it is also a common cause of death in female patients with malignant tumors in China, which seriously harms women′s health. At present, with the application of comprehensive treatment approaches, breast cancer has become one of the most effective solid tumors. Platinum drugs are widely used in malignant tumors, and they are also commonly used as effective chemotherapeutic drugs for breast cancer. To regulate the application of platinum drugs in breast cancer, the experts from Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, discuss and approve the "Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)" . This guideline is developed from the "Expert consensus on the clinical application of platinums in advanced breast cancer (2020 version)", which is updated from the latest evidence based on breast cancer at home and abroad, for platinum drugs in breast cancer clinical use, application scheme, efficacy analysis and treatment of adverse effects. This guideline aims to guide clinicians to use drugs rationally, and to further standardize the diagnosis and treatment. [ABSTRACT FROM AUTHOR]

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have led transformative breakthrough of clinical therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer patients. CDK4/6 inhibitors that have been marketed in China include Ribociclib, Palbociclib, Abemaciclib and Dalpiciclib. For HR-positive HER-2-negative locally advanced and metastatic breast cancer, CDK4/6 inhibitors combined with endocrine therapy have become standard regimen, which can prolong the survival of patients. In the adjuvant treatment stage of early breast cancer, CDK4/6 inhibitors have also achieved positive results and been approved for indications. At present, CDK4/6 inhibitors have been widely used in clinical practice in China. In order to further improve the standardized application of CDK4/6 inhibitors in China, the Breast Cancer Expert Committee of the National Center for Cancer Quality Control and the Professional Committee of Clinical Research of Cancer Drugs of the Chinese Anti-Cancer Association organized the related expert to update the consensus based on the "CDK4/6 inhibitor consensus on clinical application of in the treatment of hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer (2021 edition)" . The updated consensus systematically introduces the pharmacological characteristics, drug monitoring and adverse event management, etc., of CDK4/6 inhibitors to promote the accuracy of clinical decision-making with the ultimate goal to prolong the overall survival of patients and improve the quality of life. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common malignant tumor in women, of which the majority is early breast cancer (EBC). The strategy of postoperative adjuvant treatment relies mainly on the clinicopathologic characteristics of patients, but there are certain deficiencies if only depending on it to assess treatment benefits and disease prognosis. Multigene testing tools can evaluate the prognosis and predict therapeutic effects of breast cancer patients to guide the clinical decision-making on whether to use adjuvant chemotherapy, radiotherapy, and endocrine therapy by detecting the expression levels of specific genes. The consensus-writing expert group, based on the characteristics, validation results, and accessibility of the multigene testing tools and combined with clinical practice, described the result interpretation and clinical application of OncotypeDx® (21-gene), Mammaprint® (70-gene), RecurIndex® (28-gene), EndoPredict® (12-gene), and Breast Cancer Index® (BCI, 7-gene) for hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC. The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help guide and standardize the clinical use of multigene testing tools and further improve the level of precise treatment for EBC. [ABSTRACT FROM AUTHOR]

Antibody-drug conjugates (ADCs) are a class of targeted biological agents that link cytotoxic drugs to monoclonal antibodies through linkers. The monoclonal antibody targets tumor cells and transports small-molecule cytotoxic drugs for specific delivery and minimal off-target side effects. September 30, 2022, 14 anti-tumor ADC drugs have been approved for marketing in the world, and four ADCs have been approved in China. With the improvement of the clinical accessibility of ADC drugs, clinicians urgently need to understand the molecular characteristics and mechanisms of ADCs, and clarify the indications for rational use of drugs. Patients' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. In view of this, on the basis of the "Expert Consensus on the Clinical Application of Antibody-drug Conjugates for the Treatment of Malignant Tumors (2020 edition)", Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association fully combines the existing clinical research evidence and the feasibility of current ADC drugs in China to update the consensus content. This consensus aims to provide a systematic overview of ADC drugs, so as to provide practical and effective suggestions and references for clinicians to apply and manage ADC drugs more accurately. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor of women, which seriously threatens women's health. Albumin-bound paclitaxel is the basic chemotherapy drug for breast cancer treatment. We can promote reasonable clinical medication and improve patients' quality of life by standardizing chemotherapy plans, rationally optimizing treatment strategy and managing adverse reactions of albumin-bound paclitaxel. In order to standardize the clinical application of albumin-bound paclitaxel in breast cancer, Chinese Medical Doctor Association Oncologist Branch Breast Cancer Group and International Medical Exchange Branch of China Anti-Cancer Association consulted guidelines and the latest evidence-based evidences and formulated Chinese expert consensus of albumin-bound paclitaxel in the treatment of breast cancer to provide reference for clinical diagnosis and treatment of breast cancer. The consensus mainly introduces the clinical application strategies and evidence-based evidences of albumin-bound paclitaxel in advanced therapy, neoadjuvant therapy and adjuvant therapy of breast cancer. Among them, the regimens containing albumin-bound paclitaxel are the better recommended regimens for preoperative neoadjuvant and advanced rescue therapy of breast cancer. However, there is little evidence in adjuvant therapy, so it is recommended to use albumin-bound paclitaxel cautiously. We also invited breast cancer clinical experts to vote on some controversial issues, including but not limited to the usage and dosage of albumin-bound paclitaxel, combined medication and management of peripheral neuropathy, and formed consensus recommendations for the reference of breast cancer clinical workers. [ABSTRACT FROM AUTHOR]

The treatment of breast cancer with low expression of human epidermal growth factor receptor 2 ( HER-2) has become a focused area in recent years. With the proved therapeutic effect of antibody-drug conjugate on breast cancer patients with HER-2 low expression, HER-2-low expression may become a new subtype for targeted therapies of breast cancer. Standardized diagnosis and treatment are the foundation to guarantee efficacy. In order to improve the standardization of clinical diagnosis and treatment of HER-2-low breast cancer, the Consensus Expert Committee has summarized the latest domestic and global clinical data and the key relevant publications in recent years. We have combined them with clinical experience of pathologists and oncologists, had a deep discussion within the committee, and developed the consensus. We believe this consensus could help clinicians improve the understanding about HER-2-low breast cancer, promote the accuracy of decision-making and achieve the ultimate goal of prolonging the overall survival and improving the quality of life of patients. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common malignant tumor among women all over the world. In 2020, there were about 416 000 new cases, and more than 117 000 deaths of breast cancer in Chinese female. Of the new cases of breast cancer each year, about 3% to 10% of patients have distant metastasis at the time of diagnosis. Of the early-stage patients, about 30% developed into advanced breast cancer. The 5-year survival rate of advanced breast cancer was only 20%, and the median overall survival was 2-3 years. Although advanced breast cancer is difficult to cure at present, we can alleviate the clinical symptoms of patients, improve their quality of life and further prolong their survival time by applying new therapeutic drugs and optimizing treatment models, to achieve the purpose of long-term survival with tumor. It is very important for patients with advanced breast cancer to choose the reasonable treatment plan, and because of the lack of standard recommendation for the treatment of advanced breast cancer after the first- and second- line rescue therapies, according to the research progress of breast cancer at home and abroad and the update of real-world clinical data, the Chinese expert group analyzed, discussed and summarized the relevant research data, updated the diagnosis, treatment and prognosis of inoperable locally advanced and recurrent or metastatic breast cancer on the basis of the 2020 edition, and formulated the “Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2022 edition)” for clinicians' reference. [ABSTRACT FROM AUTHOR]

Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast cancer. Therefore, anti-cancer treatment targeting key molecules in this signaling pathway has become research hot-spot in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer. Alpelisib, a PI3K inhibitor, and everolimus, an mTOR inhibitor, have been approved by Food and Drug Administration. Based on their high efficacy and relatively good safety profile, expanded indication of everolimus in breast cancer have been approved by National Medical Products Administration. Alpelisib is expected to be approved in China in the near future. The members of the consensus expert panel reached this consensus to comprehensively define the role of PI3K/AKT/mTOR signaling pathway in breast cancer, efficacy and clinical applications of PI3K/AKT/mTOR inhibitors, management of adverse reactions, and PIK3CA mutation detection, in order to promote the understanding of PI3K/AKT/mTOR inhibitors for Chinese oncologists, improve clinical decision-making, and prolong the survival of target patient population. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common cancer in the world, and 5-year survival rate of metastatic breast cancer is about 20%. The treatment of metastatic breast cancer is mainly chemotherapy, endocrine therapy and targeted therapy. However, after multiline treatment, patients with MBC especially the triple negative breast cancer face the problem of drug resistance. Tumor angiogenesis theory suggests that blocking angiogenesis can inhibit tumor growth and migration. Based on this, angiogenesis treatment strategy is proposed. Antiangiogenic drugs mainly include biological macromolecular drugs targeting vascular endothelial growth factor ( VEGF) or vascular endothelial growth factor receptor ( VEGFR ) and small molecule VEGFR inhibitors. Angiogenesis is known to play a key role in the growth and metastasis of breast cancer. Therefore, anti-angiogenetic therapy has potential in metastatic breast cancer patients. Since the approval of tumor drug indications by NPMA in China is often later than the release of the latest research data, the National Health Commission issued " the guiding principles for the clinical application of new antitumor drugs" in 2020. The principle pointed out that under special circumstances such as the absence of better treatment, medical institutions should manage the usage of drugs that are not clearly defined in the instructions but have evidence-based data. Based on the latest research progress in breast cancer, the consensus writing expert group collated published reports, international academic conferences, conducted analysis, discussion and summary, collected data on the use of small molecule anti-vascular targeting drugs for advanced breast cancer, and formulated " expert consensus on the application of small molecule anti-angiogenic drugs in the treatment of advanced breast cancer". For clinicians' reference only. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor in women, of which early-stage (stages Ⅰ-Ⅱ) breast cancer (EBC) accounts for 73.1%. The strategy of postoperative adjuvant treatment relies mainly on the clinicopathologic characteristics of patients, but there are certain deficiencies in the assessment of treatment benefits and disease prognosis. Multigene testing tools can evaluate the prognosis and predict therapeutic effects of breast cancer patients to guide the clinical decision-making on whether to use adjuvant chemotherapy, radiotherapy, and endocrine therapy by detecting the expression levels of specific genes. The consensus-writing expert group, based on the characteristics, validation results, and accessibility of the multigene testing tools and combined with clinical practice, described the result interpretation and clinical application of OncotypeDx® (21-gene), MammaPrint® (70-gene), RecurIndex® (28-gene), and BreastCancerIndex® (BCI, 7-gene) for hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC. The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help to guide and standardize the clinical application of multigene testing tools and further improve the level of precise treatment for EBC. [ABSTRACT FROM AUTHOR]

Advanced breast cancer is a complicated disease with poor prognosis, which is difficult for salvage treatment. Although advanced breast cancer is difficult to cure at present, we can improve the life quality and prolong survival time of patients by applying optimized treatment. In recent years, with the rapid development of molecular biology and gene testing technology, studies on advanced breast cancer continue to deepen. Gene targeted therapy significantly extends the survival time of patients with advanced breast cancer. Gene testing is one of the important means for molecular typing, genetic diagnosis, therapeutic monitoring, drug resistance, and treatment choice of breast cancer, which is of great significance for the selection of targeted drugs and the management plan. In this consensus, the Expert Committee summarized ten hot issues of gene testing for advanced breast cancer and discussed the applicable population, clinical significance, and the application of molecular markers circulating tumor DNA (ctDNA), whole exome sequencing (WES) in different molecular types, and the standardization of next generation sequencing (NGS) technology applied in clinic. This consensus aimed to guide clinicians how to rationally apply the gene testing to know more comprehensive genetic testing information, and formulate more precise treatment strategies for patients with advanced breast cancer. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is one of the common malignant tumors of women. In recent years, the incidence of breast cancer is high. Human epidermal growth factor receptor-2 (HER-2) is a tyrosine kinase receptor. Breast cancer with abnormal amplification or overexpression of HER-2 have the characteristics of strong tumor invasiveness and poor prognosis. With the advent of anti-HER-2 drugs, the survival period of patients with HER-2 positive breast cancer is gradually prolonged, and the prognosis of patients with HER-2 positive breast cancer is improved. However, the efficacy of traditional HER-2 targeted drugs on patients with low expression of HER-2 is very limited, and the treatment of breast cancer with low expression of HER-2 is still facing challenges. This article reviews the standardization process of the American Society of Clinical Oncology and the American Society of Pathologists guidelines for HER-2 detection, and puts forward the data basis and possibility of defining a new subtype of breast cancer with low expression of HER-2. The birth of a new generation of HER-2 targeting drugs makes it possible to treat patients with low expression of HER-2, which will redefine breast cancer with low expression of HER-2 and provide a new opportunity for the prognosis of patients with low expression of HER-2. [ABSTRACT FROM AUTHOR]

W'ith the progress of tumor molecular biology research, the clinical treatment concept of advanced breast cancer gradually tends to he accurate. Hormone receptor ( HR ) positive and human epidermal growth factor receptor 2 ( HER-2) negative breast cancer accounts for more the 70% of all breast cancers, HR it is of great significance to exp.lore new treatment strategics to break through the bottleneck of traditional treatment faced by the patient population. Targeted therapy for this type of breast cancer started rdativdy late. After the first cydin-depcmlent kinase ( CDK) 4/6 inhibitor Palbociclib entered the clinical application for HR positive and HER-2 negative advanced cancer patients in 2015, the clinical treatment pattern of HR positive and HER-2 negative advanced breast cancer heen changed significantly, with a consequent break through improvement in patients' survival prognosis. Based on the clinic pharmacologic medumism, the author analyes the existing research data and puts formal opinions on how to achieve precise medication in clinic practice and wider application prospects in the future. [ABSTRACT FROM AUTHOR]

The introduction of cydin-depemlcnt kinase ( CDK) 4/6 inhibitors has revolutionized the clinical management paradigm of hormone receptor ( HR) positive/human epidermal growth factor receptor (HER) 2 negative breast cancer. As of today, CDK 4/6 inhibitors including, Rihocidib, and Abemacidib have been widely approved by reguratory agencies. Randomized growth demonstrated that CDK 4/6 inhibitors in combination with in aromatase inhibitor (AI) or fulvestrant in the first, second-or later-line setting for HR positive/HER2 negative locality advance or metastatic breast cancer led to substantion poluction in the risk of dislike progression or death. Adverse effects of treatment were numageablc mid as or better than expected in terms of patient satisfaction. Considering CDK4/6 inhibitors in combination with endocrine therapy being a novel approach in China clinic practice, the pand elvdoped the consensus comprehensivdy describing the pharmacology properties, monitoring strategy during treatment and adverse events numagement, to facilitate greater understanding in Chinese oncologists of a whole new therapeutic class of drug, promote accuracy of clinical decision and helpp reach the ultimate goal of improving survival mid quality of life of the terget patient population. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common and fatal malignant tumor in women, which causes great social burden throughout the world. At present, chemotherapy is still the most important treatment manner of advanced breast cancer, and platinum drugs are one of the commonly used chemotherapeutic drugs. Based on the substantial evidence, the expert committee deeply discusses the clinical application of platinum drugs in advanced breast cancer, gives the reasonable suggestions for its clinical usage, effectiveness and adverse effects. This consensus aims to guide physicians to use drugs reasonably and standardize the diagnosis and treatment. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Antibody-drug conjugate (ADC) is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head, which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells. It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs, rationally choose the appropriate dose, course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs, which may even affect the survival of patients. Therefore, the consensus aims to conduct a systematic overview of commercially available ADC drugs, provide effective recommendations and references for clinicians to better apply and manage ADC drugs. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor among women all over the world. In 2015, there were about 304,000 new cases of breast carrer in Chinese female, with more than 70,000 deaths. Of the new cases of breast cancer each year, about 3% to 10% of patients have distant metastasis at the time of diagnosis. Of the early-stage patients., about 30% developed into advanced breast cancer. The 5-years survival rate of advanced breast cancer was only 20%., and the median overall survival time was 2-3 years. Although advanced breast cancer is difficult to cure at present, we Can alleviate the clinical symptoms of patients, improve their quality of life and further prolong their survival time by developing new therapeutic drug, and optimizing treatment models, to achieve the purpose of long-term survival with tumor. It is very important for patients with advanced breast cancer to choose the reasonable treatment plan. Since there is lack of standard recommendation for the treatment of advanced breast cancer after the first and second line chemotherapy, according to the research progress of breast cancer at home and abroad and the update of real-world clinical research data, the Chinese expert group analyzed, summarized and discussed the relevant research data, updated the diagnosis, treatment and prognosis of inoperable locally advanced and recurrent or metastatic breast cancer on the basis of version 2018, and formulated the "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition)" (ABCC 2020) for clinicians' reference. [ABSTRACT FROM AUTHOR]

As a new type of anthracyclines, pegylated liposomal doxorubicin ( PLD) is widely used in the treatment of a variety of malignant tumors, including soft tissue sarcoma, ovarian cancer,breast cancer, multiple mycloma, and so on. Compared with traditional anthracydines, PLD can significantly decrease the incidences of adverse events such as cardiac toxicity and alopecia. However, the use of PLD will he accompanied with toxic side effects such as hand-foot syndrome, oral mucositis, and infusion reaction. This consensus will mainly focus on the mechanism, prevention and treatment of adverse events of PLD, in order In improve the therapeutic efficency of PLD and lifequality of patients. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor among women. Taxanes are one of the most frequently used chemotherapy regimens for breast cancer. In order to guide clinicians rational use of taxanes mid further standardize the diagnosis mid treatment of breast cancer, the expert group proposed this "Expert consensus on the clinical practice of taxanes for the treatment of breast cancer" based on substantial evidence and thorough discussion. [ABSTRACT FROM AUTHOR]

Taxanes are cornerstones of cancer chemotherapy and can he used for the treatment of various tumors, including breast cancer. Taxane-associated peripheral neuropathy is a common adverse effect of taxanes, leading to discontinuation of drug therapy, affecting drug treatment outcomes, and severely affecting patients quality of life. This consensus addresses and recommends the pathogenesis, clinical features, associated risk factors, diagnostic evaluation, prevention, and treatment of tax

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In recent years, with the emphasis on breast cancer screening and the improvement of breast cancer diagnosis and treatment, five-year survival rate and the overall survival time of breast cancer patients have been significantly improved in China. The adverse events caused by patients′ age, changes in hormone levels or anti-cancer treatment during follow-up have become new challenges in the management of patients with breast cancer, not only affecting the quality of life, but also impacting disease recurrence and death. The management of patients should not be restricted to the diagnosis and treatment of breast cancer, but to a most comprehensive management. This could improve the therapeutic efficacy of anti-cancer treatment and the quality of life of patients. Based on the current landscape of treatment and follow-up of breast cancer patients in China, the experts committee drafted the "Comprehensive Management Guideline for Breast Cancer Follow-up and Concomitant Diseases" according to the literature and relevant guidelines. This guideline is composed of four parts: path diagram, follow-up management, concomitant diseases and adverse events management. It aims to standardize the long-term follow-up of breast cancer patients, guide clinicians to deal with the concomitant diseases and adverse events, and further improve the prognosis and quality of life of breast cancer patients in China. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Estrogen has an impact on the type of lipoproteins and the blood lipid levels， thus protecting the cardiovascular system. Postmenopausal breast cancer patients suffer a significant decrease in estrogen levels due to both physiological changes and the use of drugs， and thus have a higher risk of atherosclerotic cardiovascular diseases. Therefore， strict lipid management is required for postmenopausal breast cancer patients receiving endocrine therapy. However，no guidelines have been developed in terms of lipid management and intervention for postmenopausal breast cancer patients. The Chinese expert group of multidisciplinary management of dyslipidemia in breast cancer patients with endocrine therapy， after deep investigation into the management of dyslipidemia in postmenopausal patients with early-stage breast cancer， has developed the China Expert Consensus on Dyslipidemia Management in Postmenopausal Patients with Early-stage Breast Cancer. The Consensus clearly defines the goals and measures of interventions for dyslipidemia，hoping to effectively reduce the risk of atherosclerotic cardiovascular disease in postmenopausal breast cancer patients and further improve the long-term survival of the patients. [ABSTRACT FROM AUTHOR]

In situ carcinomas of the breast constitute 15% to 30% of all newly diagnosed breast cancer cases. Although the concept of carcinoma in situ has been proposed for a long time，there is still a great controversy regarding the screening， diagnosis and treatment. This article attempts to reach some consensus on the management of ductal carcinoma in situ and lobular carcinoma in situ and provide references for clinicians in the following aspects： definition and classification， natural history and prognosis， diagnosis， local and systemic treatment for primary carcinoma in situ， recurrence risk and treatment approaches for recurrent cancers. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Ｏｂｊｅｃｔｉｖｅ 　Ｔｏ ｅｘｐｌｏｒｅ ｔｈｅ ｓａｆｅｔｙ ａｎｄ ｅｆｆｉｃａｃｙ ｏｆ ｐｅｇｙｌａｔｅｄ ｒｅｃｏｍｂｉｎａｎｔ ｈｕｍａｎ ｇｒａｎｕｌｏｃｙｔｅ ｃｏｌｏｎｙ⁃ｓｔｉｍｕｌａｔｉｎｇ ｆａｃｔｏｒ （ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ） ｉｎ ｐｒｅｖｅｎｔｉｎｇ ｃｈｅｍｏｔｈｅｒａｐｙ⁃ｉｎｄｕｃｅｄ ｎｅｕｔｒｏｐｅｎｉａ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｂｒｅａｓｔ ｃａｎｃｅｒ ａｎｄ ｎｏｎ⁃ｓｍａｌｌ ｃｅｌｌ ｌｕｎｇ ｃａｎｃｅｒ （ＮＳＣＬＣ）， ａｎｄ ｔｏ ｐｒｏｖｉｄｅ ｔｈｅ ｂａｓｉｓ ｆｏｒ ｃｌｉｎｉｃａｌ ａｐｐｌｉｃａｔｉｏｎ． Ｍｅｔｈｏｄｓ 　Ａｃｃｏｒｄｉｎｇ ｔｏ ｔｈｅ ｐｒｉｎｃｉｐｌｅ ｏｆ ｏｐｅｎ⁃ｌａｂｅｌ， ｒａｎｄｏｍｉｚｅｄ， ｐａｒａｌｌｅｌ⁃ｇｒｏｕｐ ｃｏｎｔｒｏｌｌｅｄ ｃｌｉｎｉｃａｌ ｔｒｉａｌ， ａｌｌ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｒａｎｄｏｍｉｚｅｄ ｂｙ １ ∶ １ ∶ １ ｉｎｔｏ ｔｈｒｅｅ ｇｒｏｕｐｓ ｔｏ ｒｅｃｅｉｖｅ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ １００ μｇ／ ｋｇ， ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ６ ｍｇ， ｏｒ ｒｈＧ⁃ＣＳＦ ５ μｇ／ ｋｇ， ｒｅｓｐｅｃｔｉｖｅｌｙ． Ｔｈｅ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｂｒｅａｓｔ ｃａｎｃｅｒ ｒｅｃｅｉｖｅｄ ｔｗｏ ｃｈｅｍｏｔｈｅｒａｐｙ ｃｙｃｌｅｓ， ａｎｄ ｔｈｅ ＮＳＣＬＣ ｐａｔｉｅｎｔｓ ｒｅｃｅｉｖｅｄ １⁃２ ｃｙｃｌｅｓ ｏｆ ｃｈｅｍｏｔｈｅｒａｐｙ ａｃｃｏｒｄｉｎｇ ｔｏ ｔｈｅｉｒ ｃｏｎｄｉｔｉｏｎ． Ａｌｌ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｔｒｅａｔｅｄ ｗｉｔｈ ｔｈｅ ｃｏｍｂｉｎａｔｉｏｎ ｃｈｅｍｏｔｈｅｒａｐｙ ｏｆ ＴＡＣ （ｄｏｃｅｔａｘｅｌ＋ｅｐｉｒｕｂｉｃｉｎ＋ｃｙｃｌｏｐｈｏｓｐｈａｍｉｄｅ） ｏｒ ＴＡ （ ｄｏｃｅｔａｘｅｌ ＋ ｅｐｉｒｕｂｉｃｉｎ）， ｏｒ ｔｈｅ ｃｈｅｍｏｔｈｅｒａｐｙ ｏｆ ｄｏｃｅｔａｘｅｌ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｃａｒｂｏｐｌａｔｉｎ， ｗｉｔｈ ａ ２１ ｄａｙ ｃｙｃｌｅ． Ｒｅｓｕｌｔｓ　Ｔｈｅ ｄｕｒａｔｉｏｎ ｏｆ ｇｒａｄｅ ３⁃４ ｎｅｕｔｒｏｐｅｎｉａ ｉｎ ｔｈｅ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ １００ μｇ／ ｋｇ ａｎｄ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ６ ｍｇ ｇｒｏｕｐｓ ｗｅｒｅ ｓｉｍｉｌａｒ ｗｉｔｈ ｔｈａｔ ｉｎ ｔｈｅ ｒｈＧ⁃ＣＳＦ ５ μｇ／ ｋｇ ｇｒｏｕｐ （Ｐ＞０．０５ ｆｏｒ ａｌｌ）． Ｔｈｅ ｉｎｃｉｄｅｎｃｅ ｒａｔｅ ｏｆ ｇｒａｄｅ ３⁃４ ｎｅｕｔｒｏｐｅｎｉａ ｉｎ ｔｈｅ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ １００ μｇ／ ｋｇ ｇｒｏｕｐ， ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ６ ｍｇ ｇｒｏｕｐ， ａｎｄ Ｇ⁃ＣＳＦ ５ μｇ／ ｋｇ ｇｒｏｕｐ ｗｅｒｅ ６９．７％， ６８．４％， ａｎｄ ６９．５％， ｒｅｓｐｅｃｔｉｖｅｌｙ， ｗｉｔｈ ａ ｎｏｎ⁃ｓｉｇｎｉｆｉｃａｎｔ ｄｉｆｆｅｒｅｎｃｅ ａｍｏｎｇ ｔｈｅ ｔｈｒｅｅ ｇｒｏｕｐｓ （Ｐ ＝ ０．９６３）． Ｔｈｅ ｉｎｃｉｄｅｎｃｅ ｒａｔｅ ｏｆ ｆｅｂｒｉｌｅ ｎｅｕｔｒｏｐｅｎｉａ ｉｎ ｔｈｅ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ １００ μｇ／ ｋｇ ｇｒｏｕｐ， ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ６ ｍｇ ｇｒｏｕｐ ａｎｄ Ｇ⁃ＣＳＦ ５ μｇ／ ｋｇ ｇｒｏｕｐ ｗｅｒｅ ６．１％， ６．４％， ａｎｄ ５．５％， ｒｅｓｐｅｃｔｉｖｅｌｙ， ｓｈｏｗｉｎｇ ｎｏ ｓｉｇｎｉｆｉｃａｎｔ ｄｉｆｆｅｒｅｎｃｅ ａｍｏｎｇ ｔｈｅｍ （Ｐ ＝０．９３５）． Ｔｈｅ ｉｎｃｉｄｅｎｃｅ ｒａｔｅ ｏｆ ａｄｖｅｒｓｅ ｅｖｅｎｔｓ ｉｎ ｔｈｅ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ １００ μｇ／ ｋｇ ｇｒｏｕｐ， ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ６ ｍｇ ｇｒｏｕｐ ａｎｄ Ｇ⁃ＣＳＦ ５ μｇ ／ ｋｇ ｇｒｏｕｐ ｗｅｒｅ ６．７％， ４．１％， ａｎｄ ５．５％， ｒｅｓｐｅｃｔｉｖｅｌｙ， ｓｈｏｗｉｎｇ ａ ｎｏｎ⁃ｓｉｇｎｉｆｉｃａｎｔ ｄｉｆｆｅｒｅｎｃｅ ａｍｏｎｇ ｔｈｅｍ （Ｐ ＝０．５８１）． Ｃｏｎｃｌｕｓｉｏｎｓ Ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｂｒｅａｓｔ ｃａｎｃｅｒ ａｎｄ ｎｏｎ⁃ｓｍａｌｌ ｃｅｌｌ ｌｕｎｇ ｃａｎｃｅｒ （ＮＳＣＬＣ） ｕｎｄｅｒｇｏｉｎｇ ＴＡＣ／ ＴＡ ｃｈｅｍｏｔｈｅｒａｐｙ， ａ ｓｉｎｇｌｅ １００ μｇ／ ｋｇ ｉｎｊｅｃｔｉｏｎ ｏｒ ａ ｓｉｎｇｌｅ ｆｉｘｅｄ ６ ｍｇ ｄｏｓｅ ｏｆ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ａｔ ４８ ｈｏｕｒｓ ａｆｔｅｒ ｃｈｅｍｏｔｈｅｒａｐｙ ｓｈｏｗ ｄｅｆｉｎｉｔｅ ｔｈｅｒａｐｅｕｔｉｃ ｅｆｆｅｃｔ ｗｉｔｈ ａ ｌｏｗ ｉｎｃｉｄｅｎｃｅ ｏｆ ａｄｖｅｒｓｅ ｅｖｅｎｔｓ ａｎｄ ｍｉｌｄ ａｄｖｅｒｓｅ ｒｅａｃｔｉｏｎｓ． Ｃｏｍｐａｒｅｄ ｗｉｔｈ ｔｈｅ ｃｏｎｔｉｎｕｏｕｓ ｄａｉｌｙ ｉｎｊｅｃｔｉｏｎ ｏｆ ｒｈＧ⁃ＣＳＦ ５ μｇ／ ｋｇ／ ｄ， ａ ｓｉｎｇｌｅ １００ μｇ／ ｋｇ ｉｎｊｅｃｔｉｏｎ ｏｒ ａ ｓｉｎｇｌｅ ｆｉｘｅｄ ６ ｍｇ ｄｏｓｅ ｏｆ ＰＥＧ⁃ｒｈＧ⁃ＣＳＦ ｈａｓ ｓｉｍｉｌａｒ ｅｆｆｅｃｔ ａｎｄ ｉｓ ｍｏｒｅ ａｄｖａｎｔａｇｅｏｕｓ ｉｎ ｐｒｅｖｅｎｔｉｎｇ ｃｈｅｍｏｔｈｅｒａｐｙ⁃ｉｎｄｕｃｅｄ ｎｅｕｔｒｏｐｅｎｉａ． [ABSTRACT FROM AUTHOR]

Ｏｂｊｅｃｔｉｖｅ　Ｔｏ ｅｖａｌｕａｔｅ ｔｈｅ ｅｆｆｉｃａｃｙ ａｎｄ ｓａｆｅｔｙ ｏｆ ｃｉｓｐｌａｔｉｎ ａｎｄ ｃａｐｅｃｉｔａｂｉｎｅ ｃｏｍｂｉｎａｔｉｏｎ （ＸＰ） ｔｈｅｒａｐｙ ｆｏｒ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｍｅｔａｓｔａｔｉｃ ｔｒｉｐｌｅ ｎｅｇａｔｉｖｅ ｂｒｅａｓｔ ｃａｎｃｅｒ （ ＴＮＢＣ） ｐｒｏｇｒｅｓｓｉｎｇ ａｆｔｅｒ ａｎｔｈｒａｃｙｃｌｉｎｅ ａｎｄ ｔａｘａｎｅ ｔｒｅａｔｍｅｎｔ． Ｍｅｔｈｏｄｓ 　Ｔｗｅｎｔｙ⁃ｎｉｎｅ ｍｅｔａｓｔａｔｉｃ ＴＮＢＣ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｐｒｏｓｐｅｃｔｉｖｅｌｙ ｅｎｒｏｌｌｅｄ ｔｏ ｒｅｃｅｉｖｅ ｃａｐｅｃｉｔａｂｉｎｅ （１，０００ ｍｇ／ ｍ2 ｔｗｉｃｅ ｄａｉｌｙ ｏｎ ｄａｙｓ １⁃１４） ａｎｄ ｃｉｓｐｌａｔｉｎ （７５ ｍｇ／ ｍ2 ｏｎ ｄａｙ １） ， ｒｅｐｅａｔｅｄ ｅｖｅｒｙ ３ ｗｅｅｋｓ． Ｒｅｓｕｌｔｓ　Ｗｉｔｈ ａ ｍｅｄｉａｎ ｏｆ ６ ｃｙｃｌｅｓ ｏｆ ＸＰ， ａｌｌ ２９ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｅｖａｌｕａｂｌｅ ｆｏｒ ｒｅｓｐｏｎｓｅ， ｉｎｃｌｕｄｉｎｇ １８ ＰＲ （６２．１％）， ６ ＳＤ （２０．７％）， ５ ＰＤ （１７．２％） ａｎｄ ｎｏ ＣＲ． Ｔｈｅ ｒｅｓｐｏｎｓｅ ｒａｔｅ ｗａｓ ６２．１％． Ｐａｔｉｅｎｔｓ ｗｉｔｈ ｅａｒｌｉｅｒ ｓｔａｇｅ ａｔ ｄｉａｇｎｏｓｉｓ （ｓｔａｇｅ Ⅰ ｔｏ ⅢＡ）， ｌｏｎｇｅｒ ｐｏｓｔ⁃ｏｐｅｒａｔｉｖｅ ｄｉｓｅａｓｅ ｆｒｅｅ ｓｕｒｖｉｖａｌ （＞２ ｙｅａｒｓ） ａｎｄ ｌｅｓｓ ｍｅｔａｓｔａｔｉｃ ｓｉｔｅｓ （≤３） ｏｂｔａｉｎｅｄ ｓｉｇｎｉｆｉｃａｎｔｌｙ ｈｉｇｈｅｒ ｒｅｓｐｏｎｓｅ ｒａｔｅ ｔｈａｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｌａｔｅｒ ｓｔａｇｅ ａｔ ｄｉａｇｎｏｓｉｓ （ｓｔａｇｅ ⅢＢ ｔｏ Ⅳ）， ｓｈｏｒｔｅｒ ｐｏｓｔ⁃ｏｐｅｒａｔｉｖｅ ｄｉｓｅａｓｅ ｆｒｅｅ ｓｕｒｖｉｖａｌ （≤２ ｙｅａｒｓ） ａｎｄ ｍｏｒｅ ｍｅｔａｓｔａｔｉｃ ｓｉｔｅｓ （＞３）． Ｔｈｅ ｌｅａｄｉｎｇ ｓｉｄｅ ｅｆｆｅｃｔｓ ｗｅｒｅ ｇｒａｄｅ １／２ ｇａｓｔｒｏｉｎｔｅｓｔｉｎａｌ ａｎｄ ｈｅｍａｔｏｌｏｇｉｃａｌ ｔｏｘｉｃｉｔｉｅｓ． Ｇｒａｄｅ ３／４ ｔｏｘｉｃｉｔｉｅｓ ｉｎｃｌｕｄｅｄ ｎｅｕｔｒｏｐｅｎｉａ （ ３４． ５％）， ｌｅｕｋｏｃｙｔｏｐｅｎｉａ （ ３１． ０％）， ａｎｅｍｉａ （ ６． ９％）， ｔｈｒｏｍｂｏｃｙｔｏｐｅｎｉａ （３． ４％）， ｎａｕｓｅａ／ ｖｏｍｉｔｉｎｇ （ ２０． ７％）， ｓｔｏｍａｔｉｔｉｓ （ ３． ４％）， ａｎｄ ｈａｎｄ⁃ｆｏｏｔ ｓｙｎｄｒｏｍｅ （３．４％）． Ｃｏｎｃｌｕｓｉｏｎ 　Ｃｉｓｐｌａｔｉｎ ａｎｄ ｃａｐｅｃｉｔａｂｉｎｅ ｃｏｍｂｉｎａｔｉｏｎ ｔｈｅｒａｐｙ ｉｓ ａｎ ａｃｔｉｖｅ ａｎｄ ｗｅｌｌ⁃ｔｏｌｅｒａｔｅｄ ｄｏｕｂｌｅｔ ｔｒｅａｔｍｅｎｔ ｉｎ ｍｅｔａｓｔａｔｉｃ ＴＮＢＣ ｐａｔｉｅｎｔｓ ｐｒｏｇｒｅｓｓｉｎｇ ａｆｔｅｒ ａｎｔｈｒａｃｙｃｌｉｎｅ ａｎｄ ｔａｘａｎｅ ｔｒｅａｔｍｅｎｔｓ． [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)